Download MendeleyDeciphering the role of Enterococcus faecium cytidine deaminase in gemcitabine resistance of gallbladder cancer.
Jiang, L., Zhang, L., Shu, Y., Zhang, Y., Gao, L., Qiu, S., Zhang, W., Dai, W., Chen, S., Huang, Y., Liu, Y.(2024) J Biological Chem 300: 107171-107171
- PubMed: 38492776
- DOI: https://doi.org/10.1016/j.jbc.2024.107171
- Primary Citation of Related Structures:
8X6U, 8X6W, 8X6Y - PubMed Abstract:
Gemcitabine-based chemotherapy is a cornerstone of standard care for gallbladder cancer (GBC) treatment. Still, drug resistance remains a significant challenge, influenced by factors such as tumor-associated microbiota impacting drug concentrations within tumors. Enterococcus faecium, a member of tumor-associated microbiota, was notably enriched in the GBC patient cluster. In this study, we investigated the biochemical characteristics, catalytic activity, and kinetics of the cytidine deaminase of E. faecium (EfCDA). EfCDA showed the ability to convert gemcitabine to its metabolite 2',2'-difluorodeoxyuridine. Both EfCDA and E. faecium can induce gemcitabine resistance in GBC cells. Moreover, we determined the crystal structure of EfCDA, in its apo form and in complex with 2', 2'-difluorodeoxyuridine at high resolution. Mutation of key residues abolished the catalytic activity of EfCDA and reduced the gemcitabine resistance in GBC cells. Our findings provide structural insights into the molecular basis for recognizing gemcitabine metabolite by a bacteria CDA protein and may provide potential strategies to combat cancer drug resistance and improve the efficacy of gemcitabine-based chemotherapy in GBC treatment.
- School of Health Science and Engineering, University of Shanghai for Science and Technology, Shanghai, China; Department of General Surgery, Shanghai Research Center of Biliary Tract Disease, Shanghai Key Laboratory of Biliary Tract Disease Research, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Organizational Affiliation:
